Published on 19/09/202519/09/2025 by Cell Biologist Prof. Dr. Rizwan Khan | Diabetic Neuropathy | Best Researcher Award Aligarh Muslim University | India Dr. Rizwan Hasan Khan is a distinguished professor at the Interdisciplinary Biotechnology Unit of Aligarh Muslim University, specializing in biophysical chemistry and molecular interactions related to protein aggregation and therapeutic drug design. With a Ph.D. awarded focused on lectins, Dr. Khan has significantly contributed to understanding protein fibrillation, aggregation mechanisms, and their inhibition, particularly in relation to amyloid diseases and antimicrobial resistance. His research encompasses the biophysical characterization of proteins, the impact of toxins and drugs on protein behavior, and the identification of novel inhibitors through computational and experimental approaches. Dr. Khan’s prolific output includes over 16 peer-reviewed research and review articles published in reputed journals such as Biophysical Chemistry, Archives of Biochemistry and Biophysics, and Cell Reports, reflecting interdisciplinary expertise in biotechnology, biochemistry, and drug discovery. His work has attracted citations highlighting its influence in the fields of amyloid research and therapeutic development. Dr. Khan maintains an h-index indicative of sustained scholarly impact, underscoring his role as a leading researcher in molecular biophysics and pharmacology. His research continues to advance knowledge in combating protein aggregation disorders and antimicrobial resistance, contributing valuable insights into novel drug candidates and molecular mechanisms. Profiles: Google Scholar | Scopus Featured Publications: “Inhibition of nucleation and disruption of amyloid fibrillation in human lysozyme aggregation by a potent Cu (II) flufenamate chemotherapeutic drug candidate” “Ponceau 4R induces aggregation in human serum albumin and morin acts as an anti-aggregating agent against dye induced aggregates” “Hippuric acid, a uremic toxin, binds to aggregation prone region of human lysozyme and potentiates the fibrillation: A biophysical insight” “Identification of potential inhibitors of Ubiquitin carboxyl-terminal hydrolase 21 from repurposed drugs: Implications in anticancer therapeutics” “Loss of Neurofibromin Induces Inflammatory Macrophage Phenotypic Switch and Retinal Neovascularization via GLUT1 Activation” “Employing spectroscopic, calorimetric and structural bioinformatics approaches to decipher the binding mechanism of mangiferin with human transferrin” “Interaction of Esculetin with Alpha-2-Macroglobulin: Biochemical and Biophysical Approaches” “Utilizing non-β-lactam antibiotics to combat antimicrobial resistance by targeting multiple virulence factors of Pseudomonas aeruginosa” “Strategies for inhibiting amyloid fibrillation: Current status and future prospects” “Assessing the role of Berberine as an inhibitor of advanced glycation end products (AGEs) formation using in vitro and molecular interaction studies” Rizwan Khan | Diabetic Neuropathy | Best Researcher Award
Dr. Rizwan Hasan Khan is a distinguished professor at the Interdisciplinary Biotechnology Unit of Aligarh Muslim University, specializing in biophysical chemistry and molecular interactions related to protein aggregation and therapeutic drug design. With a Ph.D. awarded focused on lectins, Dr. Khan has significantly contributed to understanding protein fibrillation, aggregation mechanisms, and their inhibition, particularly in relation to amyloid diseases and antimicrobial resistance. His research encompasses the biophysical characterization of proteins, the impact of toxins and drugs on protein behavior, and the identification of novel inhibitors through computational and experimental approaches. Dr. Khan’s prolific output includes over 16 peer-reviewed research and review articles published in reputed journals such as Biophysical Chemistry, Archives of Biochemistry and Biophysics, and Cell Reports, reflecting interdisciplinary expertise in biotechnology, biochemistry, and drug discovery. His work has attracted citations highlighting its influence in the fields of amyloid research and therapeutic development. Dr. Khan maintains an h-index indicative of sustained scholarly impact, underscoring his role as a leading researcher in molecular biophysics and pharmacology. His research continues to advance knowledge in combating protein aggregation disorders and antimicrobial resistance, contributing valuable insights into novel drug candidates and molecular mechanisms. Profiles: Google Scholar | Scopus Featured Publications: “Inhibition of nucleation and disruption of amyloid fibrillation in human lysozyme aggregation by a potent Cu (II) flufenamate chemotherapeutic drug candidate” “Ponceau 4R induces aggregation in human serum albumin and morin acts as an anti-aggregating agent against dye induced aggregates” “Hippuric acid, a uremic toxin, binds to aggregation prone region of human lysozyme and potentiates the fibrillation: A biophysical insight” “Identification of potential inhibitors of Ubiquitin carboxyl-terminal hydrolase 21 from repurposed drugs: Implications in anticancer therapeutics” “Loss of Neurofibromin Induces Inflammatory Macrophage Phenotypic Switch and Retinal Neovascularization via GLUT1 Activation” “Employing spectroscopic, calorimetric and structural bioinformatics approaches to decipher the binding mechanism of mangiferin with human transferrin” “Interaction of Esculetin with Alpha-2-Macroglobulin: Biochemical and Biophysical Approaches” “Utilizing non-β-lactam antibiotics to combat antimicrobial resistance by targeting multiple virulence factors of Pseudomonas aeruginosa” “Strategies for inhibiting amyloid fibrillation: Current status and future prospects” “Assessing the role of Berberine as an inhibitor of advanced glycation end products (AGEs) formation using in vitro and molecular interaction studies”